The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease
The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease
复制标题
益生菌干酪乳杆菌可减缓急性和慢性肾脏疾病的进展。
DOI：
10.1016/j.cmet.2021.06.014
复制
发表时间：
2021-10-05
期刊：
影响因子：
29
通讯作者：
Zeng, Rui
中科院分区：
文献类型：
--
作者：
Zhu, Han;Cao, Chujin;Zeng, Rui
肠道微生物生态失调与急性或慢性肾脏疾病（CKD）之间的关系尚不清楚。在这里，我们表明，口服益生菌干酪乳杆菌张（L。casei Zhang）纠正了小鼠双侧肾缺血-再灌注（I/R）诱导的肠道微生物生态失调，减轻了肾损伤，并延缓了其向CKD的进展。L. casei Zhang升高了血清和肾脏中短链脂肪酸（SCFAs）和烟酰胺的水平，从而减少了肾脏炎症和肾小管上皮细胞的损伤。我们还进行了一项为期1年的口服L。casei Zhang使用（中国临床试验注册中心，ChiCTR-INR-17013952），其耐受性良好，并减缓了3-5期CKD患者的肾功能下降。这些结果表明，口服L。通过改变SCFAs和烟酰胺代谢，casei Zhang是减轻肾损伤和减缓肾功能衰退进展的潜在疗法。
The relationship between gut microbial dysbiosis and acute or chronic kidney disease (CKD) is still unclear. Here, we show that oral administration of the probiotic Lactobacillus casei Zhang (L. casei Zhang) corrected bilateral renal ischemia-reperfusion (I/R)-induced gut microbial dysbiosis, alleviated kidney injury, and delayed its progression to CKD in mice. L. casei Zhang elevated the levels of short-chain fatty acids (SCFAs) and nicotinamide in the serum and kidney, resulting in reduced renal inflammation and damage to renal tubular epithelial cells. We also performed a 1-year phase 1 placebo-controlled study of oral L. casei Zhang use (Chinese clinical trial registry, ChiCTR-INR-17013952), which was well tolerated and slowed the decline of kidney function in individuals with stage 3-5 CKD. These results show that oral administration of L. casei Zhang, by altering SCFAs and nicotinamide metabolism, is a potential therapy to mitigate kidney injury and slow the progression of renal decline.